/
ENSC
$0.30-$0.00 (-1.40%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$4.6M
15M shares
52-week range
$0.23 – $2.75
3% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
38.16%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-52199.70
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.8M | $3.9M | $3.5M | $2.5M | $2.2M | $5.2M | $5.1M |
| Cost of revenue | $1.6M | $3.4M | $201 | $151 | $19.8M | $7.6M | $7.2M | $0 |
| Gross profit | −$1.6M | −$1.6M | $3.9M | $3.5M | −$17.3M | −$5.4M | −$2.0M | $0 |
| Gross margin | — | -92.9% | 100.0% | 100.0% | -686.1% | -240.1% | -38.6% | 0.0% |
| R&D | $0 | $3.4M | $4.4M | $4.7M | $19.8M | $7.6M | $7.2M | $10.4M |
| Operating income | −$959.0K | −$8.6M | −$1.6M | −$19.9M | −$24.2M | −$10.7M | −$6.7M | −$10.2M |
| EBITDA | $2.7M | −$8.6M | $834.8K | −$25.9M | −$24.2M | −$10.7M | −$6.7M | −$10.2M |
| Net income | −$1.3M | −$10.1M | $56.8K | −$29.1M | −$24.2M | −$10.6M | −$8.0M | −$10.2M |
| Net margin | — | -572.7% | 1.4% | -823.6% | -957.9% | -475.7% | -153.3% | -200.8% |
| EPS (diluted) | -0.22 | 0.24 | 0.56 | -355.68 | -139.44 | -4.69 | -4.57 | -3.98 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $7M | $-1.98 | $-1.98–$-1.98 | 1 |
| 2027 | $3M | $-0.11 | $-0.11–$-0.11 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Ensysce Biosciences, Inc. Common Stock
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
www.ensysce.com- Employees
- 10
- IPO / List date
- Jul 1, 2021
- HQ
- LA JOLLA, CA
Held by traders on TradeandTell
No one on the platform currently holds ENSC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 15,574 | $36.9K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-12-06 | 1-for-15reverse |
| 2023-03-31 | 1-for-12reverse |
| 2022-10-28 | 1-for-20reverse |
| 2006-07-27 | 1-for-1000reverse |
Recent trades on TradeandTell
No one on the platform has traded ENSC yet.
